港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

寶濟藥業-B

21.880

-1.160-5.03%

成交量：187.76萬

成交額：4,197.99萬

市值：71.32億

市盈率：-13.89

高：23.300

開：22.800

低：21.800

收：23.040

52周最高：206.000

52周最低：21.800

股本：3.26億

香港流通股本：1.54億

量比：0.67

換手率：1.22%

股息：- -

股息率：- -

每股收益(LYR):-1.576

淨資產收益率：-30.55%

總資產收益率：-10.79%

市淨率：3.87

市盈率(LYR):-13.89

市銷率: 125.25

資料載入中...

總覽公司新聞資訊公告

寶濟藥業-B4月無新增發行或股份變動

異動解讀 | 寶濟藥業-B盤中大跌6.39%，增持及回購授權提振效果消退市場信心再度承壓

寶濟藥業-B將回購不超過10%已發行H股股份

異動解讀 | 寶濟藥業-B盤中大漲6.20%，董事會主席擬增持股份提振信心

寶濟藥業-B(02659)擬獲董事會主席劉彥君博士增持股份

寶濟藥業(02659.HK)確認不悉股價波動原因主席擬增持

阿斯达克财经

日內閃崩65%，港股創新藥又現慘案

異動解讀 | 寶濟藥業-B盤中暴跌65.42%，年報淨虧損擴大引發市場擔憂

寶濟藥業－Ｂ(02659)股價大幅下跌55.941%，現價港幣$33.0

阿斯达克财经

寶濟藥業-B：2025年主營業務快速推進，收入顯著增長並強化研發與資本實力

異動解讀 | 產品獲批及臨床試驗受理，寶濟藥業-B盤中大漲11.95%

寶濟藥業－Ｂ(02659)股價大幅下跌32.82%，現價港幣$52.3

阿斯达克财经

從Biotech到18A板塊「底層運營商」，寶濟藥業-B（02659）如何扼守千億市場的「入場券」

寶濟藥業－Ｂ(02659)出現大手買入8.65萬股，成交價$90.95，涉資786.718萬

阿斯达克财经

寶濟藥業(02659)重組烏司他丁(BJ044)IND申請獲受理，開啓重組蛋白藥物新紀元

靜脈轉皮下的革命已至，KJ017正式獲批，寶濟藥業（02659）正成為大分子藥物生態的「樞紐核心」

寶濟藥業－Ｂ(02659)出現大手買入6.75萬股，成交價$100.0，涉資675萬

阿斯达克财经

寶濟藥業－Ｂ(02659)股價上升8.271%，現價港幣$116.5

阿斯达克财经

異動解讀 | 核心產品KJ017獲批上市，寶濟藥業-B盤中大漲5.02%

瞄準生物製藥「卡脖子」難題，寶濟藥業(02659)給出技術驅動高質量發展答案

智通财经网

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/02659/news?page=2"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"02659","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","market":"HK","secType":"STK","nameCN":"寶濟藥業-B","latestPrice":21.88,"timestamp":1780387724966,"preClose":23.04,"halted":0,"volume":1877600,"delay":0,"changeRate":-0.05034722222222223,"floatShares":154000000,"shares":325981465,"eps":-1.575558673009554,"marketStatus":"未開盤","change":-1.16,"latestTime":"06-02 16:08:44","open":22.8,"high":23.3,"low":21.8,"amount":41979880,"amplitude":0.065104,"askPrice":21.88,"askSize":1200,"bidPrice":21.86,"bidSize":3600,"shortable":0,"etf":0,"ttmEps":-1.5558641895969345,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1780450200000},"marketStatusCode":0,"adr":0,"listingDate":1765296000000,"exchange":"SEHK","adjPreClose":23.04,"openAndCloseTimeList":[[1780363800000,1780372800000],[1780376400000,1780387200000]],"volumeRatio":0.674881,"lotSize":100,"spreadScale":0,"tradeCurrency":"HKD"},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"02659\",,,,,undefined,":{"symbol":"02659","floatShares":154000000,"roa":"-10.79%","roe":"-30.55%","lyrEps":-1.575559,"volumeRatio":0.674881,"shares":325981465,"dividePrice":0,"high":23.3,"amplitude":0.065104,"preClose":23.04,"low":21.8,"week52Low":21.8,"pbRate":"3.87","psRate":"125.25","week52High":206,"institutionHeld":0,"latestPrice":21.88,"committee":0.5,"eps":-1.575558673009554,"divideRate":0,"volume":1877600,"delay":0,"ttmEps":-1.5558641895969345,"open":22.8,"prevYearClose":77.55,"prevWeekClose":24.54,"prevMonthClose":24.54,"prevQuarterClose":91.3,"fiveDayClose":24.94,"twentyDayClose":26.02,"sixtyDayClose":154.4},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/02659\",params:#limit:5,,,undefined,":[{"date":"2026-03-26","symbol":"02659","type":"earning","reportTimeType":"","market":"HK","fiscalQuarterEnding":null,"expectedEps":null,"defaultRemindTime":1774488600000,"name":null,"time":"","dateTimestamp":1774454400000,"actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"02659\",market:\"HK\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"02659\",market:\"HK\",delay:false,,,undefined,":{"strongBuy":0,"buy":1,"hold":0,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":1,"analysts":2,"updateTime":1779984000000},"@#url:\"https://hq.skytigris.cn/hkstock/value_analysis/stock/02659\",params:#withQuantilePoint:true,period:\"5year\",factor:\"peRate\",delay:false,algorithm:1,,,undefined,":{"brief":{"id":"02659","date":"2026-06-01","current":-14.061102,"percent":1,"low":-150.791275,"twenty":-78.760123,"median":-66.033023,"eighty":-50.330094,"high":-16.403454,"avg":-65.878371,"sd":31.445175,"marketCap":7510612953},"quantilePoints":[{"date":"2025-12-12","current":-53.146224,"twenty":-53.348389,"median":-51.086695,"eighty":-37.627242,"marketCap":22280833132},{"date":"2025-12-19","current":-56.628418,"twenty":-56.115318,"median":-53.146224,"eighty":-50.330094,"marketCap":23796646945},{"date":"2025-12-24","current":-60.667186,"twenty":-57.368285,"median":-54.841733,"eighty":-51.357726,"marketCap":25573245929},{"date":"2026-01-02","current":-53.689307,"twenty":-58.867149,"median":-56.13619,"eighty":-51.993778,"marketCap":22720908110},{"date":"2026-01-09","current":-60.663453,"twenty":-59.744205,"median":-56.240552,"eighty":-53.146224,"marketCap":25736236661},{"date":"2026-01-16","current":-77.814349,"twenty":-61.547088,"median":-57.565784,"eighty":-53.651638,"marketCap":33119716844},{"date":"2026-01-23","current":-76.125836,"twenty":-72.759479,"median":-58.867149,"eighty":-53.689307,"marketCap":32369959474},{"date":"2026-01-30","current":-79.366151,"twenty":-76.125836,"median":-60.665319,"eighty":-55.0155,"marketCap":33902072360},{"date":"2026-02-06","current":-84.493791,"twenty":-76.125836,"median":-61.547088,"eighty":-55.626475,"marketCap":36183942615},{"date":"2026-02-13","current":-126.016863,"twenty":-78.017279,"median":-67.830536,"eighty":-56.031828,"marketCap":54275913922},{"date":"2026-02-20","current":-138.174242,"twenty":-79.686668,"median":-71.167377,"eighty":-56.115318,"marketCap":59426421069},{"date":"2026-02-27","current":-116.132786,"twenty":-104.714701,"median":-73.426035,"eighty":-56.395698,"marketCap":50494528928},{"date":"2026-03-06","current":-76.640212,"twenty":-111.983375,"median":-74.892856,"eighty":-56.998352,"marketCap":33054520551},{"date":"2026-03-13","current":-75.987902,"twenty":-110.582832,"median":-75.36732,"eighty":-57.563278,"marketCap":32924127965},{"date":"2026-03-20","current":-70.725897,"twenty":-109.509649,"median":-74.892856,"eighty":-57.733099,"marketCap":30528164197},{"date":"2026-03-27","current":-65.400661,"twenty":-104.714701,"median":-74.674242,"eighty":-58.326024,"marketCap":29273135557},{"date":"2026-04-02","current":-74.510382,"twenty":-96.653813,"median":-73.605533,"eighty":-59.04256,"marketCap":33510894602},{"date":"2026-04-10","current":-71.602503,"twenty":-91.308972,"median":-74.057958,"eighty":-59.568794,"marketCap":32451454840},{"date":"2026-04-17","current":-64.454748,"twenty":-86.399914,"median":-73.087213,"eighty":-60.479603,"marketCap":29224238337},{"date":"2026-04-24","current":-55.967849,"twenty":-84.718643,"median":-71.1642,"eighty":-60.173931,"marketCap":25377657050},{"date":"2026-04-30","current":-18.543355,"twenty":-83.426575,"median":-70.300184,"eighty":-58.506399,"marketCap":8410321797},{"date":"2026-05-08","current":-19.625214,"twenty":-81.092081,"median":-69.74185,"eighty":-56.760202,"marketCap":8931892141},{"date":"2026-05-15","current":-17.930681,"twenty":-79.944236,"median":-68.961959,"eighty":-55.831299,"marketCap":8182134771},{"date":"2026-05-22","current":-17.55647,"twenty":-79.579829,"median":-66.237091,"eighty":-53.674239,"marketCap":7993065521},{"date":"2026-05-29","current":-17.509903,"twenty":-78.962132,"median":-66.085797,"eighty":-51.516739,"marketCap":7999585151},{"date":"2026-06-01","current":-16.403454,"twenty":-78.760123,"median":-66.033023,"eighty":-50.330094,"marketCap":7510612953}],"updateTime":1780420589899},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"02659\",pageSize:20,pageCount:2,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1167341527","title":"寶濟藥業-B4月無新增發行或股份變動","url":"https://stock-news.laohu8.com/highlight/detail?id=1167341527","media":"公告速递","labels":["SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1167341527?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 17:33","pubTimestamp":1778060037,"startTime":"0","endTime":"0","summary":"上海宝济药业股份有限公司于2026年5月6日公布截至2026年4月30日的证券变动月报表。根据公告信息，本月公司股本结构及已发行股份数均保持稳定，未发生新增发行、购回、注销或库藏股等变动。据月报显示，报告期内，公司法定/注册股本总额为人民币65,196,293元。公告同时披露，本月未发生股份期权及股权激励计划变动事宜，也无任何购回或注销活动。公告由执行董事刘彦君签署。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"8d4c202617d87be1d9fe31f833a300a8","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1164479567","title":"異動解讀 | 寶濟藥業-B盤中大跌6.39%，增持及回購授權提振效果消退市場信心再度承壓","url":"https://stock-news.laohu8.com/highlight/detail?id=1164479567","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1164479567?lang=zh_tw&edition=fundamental","pubTime":"2026-05-06 10:52","pubTimestamp":1778035975,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大跌6.39%，引发了市场关注。消息面上，尽管公司董事会主席此前宣布拟增持股份并提呈股份购回授权，但市场对其实际执行力存疑。回购仅为授权而非承诺，且公司近三年累计亏损高达9.19亿元，资金实力不足可能制约回购计划落地。此外，该股在经历此前闪崩暴跌及短暂反弹后，买盘动能减弱，获利回吐压力与基本面忧虑交织，导致股价再度走低。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1187419400","title":"寶濟藥業-B將回購不超過10%已發行H股股份","url":"https://stock-news.laohu8.com/highlight/detail?id=1187419400","media":"公告速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1187419400?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 20:35","pubTimestamp":1777898158,"startTime":"0","endTime":"0","summary":"宝济药业-B日前在股东周年大会上通过授权，拟回购不超过公司已发行H股股份10%的股份。根据公告，截至最后实际可行日期，公司已发行H股总数为154,327,250股，按此计算，回购规模最高可达约15,432,725股。公司强调，本次回购完成后，将根据实际进度及时公布后续安排或审议结果，相关股东大会重要时间节点及过户日期另行公告。董事会发声明称，回购资金合法合规，不会影响公司的正常运营及资金调配，并符合上市法规及整体股东的最佳利益。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B将回购不超过10%已发行H股股份","news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1194276733","title":"異動解讀 | 寶濟藥業-B盤中大漲6.20%，董事會主席擬增持股份提振信心","url":"https://stock-news.laohu8.com/highlight/detail?id=1194276733","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194276733?lang=zh_tw&edition=fundamental","pubTime":"2026-05-04 09:32","pubTimestamp":1777858375,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨6.20%，引起了市场的广泛关注。消息面上，公司董事会主席兼控股股东刘彦君博士发布公告，基于对公司前景及增长潜力的信心，以及对其长期投资价值的认可，计划自公告日期起3个月内通过公开市场交易增持公司股份。控股股东的增持意向向市场传递了积极的信号，增强了投资者对公司的信心。根据公告，于公告日期，控股股东集团持有公司已发行股份总数约40.57%。在增持计划实施后，控股股东的总持股量预计不会触发强制要约责任，且公司将继续遵守相关上市规则中的最低公众持股量规定。","market":"nz","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632760250","title":"寶濟藥業-B(02659)擬獲董事會主席劉彥君博士增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2632760250","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632760250?lang=zh_tw&edition=fundamental","pubTime":"2026-05-03 18:57","pubTimestamp":1777805832,"startTime":"0","endTime":"0","summary":"智通财经APP讯，宝济药业-B 发布公告，本公司收到董事会主席兼本公司控股股东集团成员刘彦君博士的通知，基于其对本集团前景及增长潜力的信心，以及其对本公司长期投资价值的认可，其拟自本公告日期起3个月内透过公开市场交易增持本公司股份。于本公告日期，控股股东集团于合共2595.69万股H股及1.06亿股内资股中拥有权益，占本公司已发行股份总数约40.57%。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1437694.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2632602656","title":"寶濟藥業(02659.HK)確認不悉股價波動原因  主席擬增持","url":"https://stock-news.laohu8.com/highlight/detail?id=2632602656","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2632602656?lang=zh_tw&edition=fundamental","pubTime":"2026-05-03 18:55","pubTimestamp":1777805700,"startTime":"0","endTime":"0","summary":"宝济药业－Ｂ(02659.HK) 就股价及成交量异常波动声明，确认并不知悉导致波动的任何原因，亦确认业务营运维持正常，且业务营运及财务状况并无重大变动。同时，建议回购最多占H股总数10%的公司股份。此外，主席兼控股股东集团刘彦君博士拟即日起三个月内增持公司股份，收购的最高股数不得超过3,889.39万股。该股上交易日(30日)收报25.8元，下跌49.1元，跌幅65.55%，成交2,600万股，成交额7.85亿元。(de/d)(港股报价延迟最少十五分钟。)AASTOCKS新闻","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20260126145024008_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20260126145024008_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1522184/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1522184/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631636437","title":"日內閃崩65%，港股創新藥又現慘案","url":"https://stock-news.laohu8.com/highlight/detail?id=2631636437","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631636437?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 19:18","pubTimestamp":1777547895,"startTime":"0","endTime":"0","summary":"北水何其无辜","market":"fut","thumbnail":"https://img2.gelonghui.com/04ed9-165b80a9-8840-4f0d-8280-6ab34d3076ce.jpg?guru_height=903&guru_width=1365&guru_size=101270","type":0,"news_type":0,"thumbnails":["https://img2.gelonghui.com/04ed9-165b80a9-8840-4f0d-8280-6ab34d3076ce.jpg?guru_height=903&guru_width=1365&guru_size=101270"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/p/4615644","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"gelonghui_highlight","symbols":["06978","BK1574","VXUS","159992","02659","BK4585","BK4588","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1114872175","title":"異動解讀 | 寶濟藥業-B盤中暴跌65.42%，年報淨虧損擴大引發市場擔憂","url":"https://stock-news.laohu8.com/highlight/detail?id=1114872175","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1114872175?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 14:36","pubTimestamp":1777531001,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅下挫，跌幅一度达到65.42%，引起了市场的广泛关注。消息面上，公司近期披露的年报数据显示，尽管2025年营业收入实现大幅增长，但归母净利润亏损进一步扩大至3.95亿元，较上年同期的净亏损3.64亿元有所增加。持续且扩大的亏损引发了投资者对公司盈利能力和未来前景的担忧，可能是导致股价在交易时段内闪崩的重要原因。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2631506487","title":"寶濟藥業－Ｂ(02659)股價大幅下跌55.941%，現價港幣$33.0","url":"https://stock-news.laohu8.com/highlight/detail?id=2631506487","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2631506487?lang=zh_tw&edition=fundamental","pubTime":"2026-04-30 13:05","pubTimestamp":1777525500,"startTime":"0","endTime":"0","summary":"[下跌股]宝济药业－Ｂ(02659) 股价在下午01:05比前收市价大幅下跌55.941%，现股价为港币$33.0。至目前为止，今日最高价为$74.7，而最低价为$33.0。总成交量为196.18万股，总成交金额为港币$1.027亿。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150425748_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604303830/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604303830/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1103101923","title":"寶濟藥業-B：2025年主營業務快速推進，收入顯著增長並強化研發與資本實力","url":"https://stock-news.laohu8.com/highlight/detail?id=1103101923","media":"公告速递","labels":["dataReport","SGX"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1103101923?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 19:09","pubTimestamp":1777288199,"startTime":"0","endTime":"0","summary":"宝济药业-B是一家专注合成生物技术的生物医药企业，核心布局在自身免疫性疾病、大容量皮下给药、辅助生殖及重组生物制剂等领域。截至2025年，公司持续推进12款自主研发药物管线，其中KJ017、KJ103及SJ02为核心候选产品。总体而言，2025年对宝济药业-B具有里程碑意义：一方面，公司在核心产品推广、全球化布局与新产品研发上均取得扎实进展；另一方面，上市为其进一步拓展资金与资源打开新局面。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"宝济药业-B：2025年主营业务快速推进，收入显著增长并强化研发与资本实力","news_tag":"dataReport,SGX","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1179144809","title":"異動解讀 | 產品獲批及臨床試驗受理，寶濟藥業-B盤中大漲11.95%","url":"https://stock-news.laohu8.com/highlight/detail?id=1179144809","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1179144809?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 15:20","pubTimestamp":1777274442,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中大涨11.95%，引起了市场的广泛关注。消息面上，宝济药业自主研发的重组乌司他丁（BJ044）临床试验申请已正式获得国家药品监督管理局受理，该产品与公司另一重点产品重组人糜蛋白酶KJ101的临床进展形成了明确的战略协同。此外，公司核心品种注射用人玻璃酸酶（葆舒宜®）已正式获得国家药监局批准上市。西牛证券此前指出，公司产品于中国具有先发优势，预计相关产品将于2026年开始为公司带来显著的收入贡献，这增强了市场对公司未来业绩增长的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2630355112","title":"寶濟藥業－Ｂ(02659)股價大幅下跌32.82%，現價港幣$52.3","url":"https://stock-news.laohu8.com/highlight/detail?id=2630355112","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2630355112?lang=zh_tw&edition=fundamental","pubTime":"2026-04-27 10:30","pubTimestamp":1777257000,"startTime":"0","endTime":"0","summary":"[下跌股]宝济药业－Ｂ(02659) 股价在上午10:30比前收市价大幅下跌32.82%，现股价为港币$52.3。至目前为止，今日最高价为$77.95，而最低价为$52.3。总成交量为59.6万股，总成交金额为港币$3.675千万。","market":"fut","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133703138_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604271051/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2604271051/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2629702540","title":"從Biotech到18A板塊「底層運營商」，寶濟藥業-B（02659）如何扼守千億市場的「入場券」","url":"https://stock-news.laohu8.com/highlight/detail?id=2629702540","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2629702540?lang=zh_tw&edition=fundamental","pubTime":"2026-04-23 09:54","pubTimestamp":1776909264,"startTime":"0","endTime":"0","summary":"在港股18A生物医药板块步入“价值回归”的2026年，一场关于“生物制造工业化”与“给药场景革命”的深刻范式转移正在悄然发生。在这一宏大的行业叙事中，宝济药业-B正另辟蹊径，凭借其独特的合成生物学底座与“场景驱动”战略，从一家传统的Biotech公司进化为中国生物医药产业升级的关键“连接器”。当前，宝济药业在上海、江苏等地布局近10万平方米生产基地、2.6万升反应器容积并配备超过70%的研发人员。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1432432.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK4581","02659","BK4588","BK1161","BK4585","XBI"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628771867","title":"寶濟藥業－Ｂ(02659)出現大手買入8.65萬股，成交價$90.95，涉資786.718萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2628771867","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628771867?lang=zh_tw&edition=fundamental","pubTime":"2026-04-20 10:15","pubTimestamp":1776651300,"startTime":"0","endTime":"0","summary":"[大手成交]宝济药业－Ｂ(02659)在上午10:15出现大手买入，成交量为8.65万，成交价为港币$90.95，涉资786.718万。至目前为止，股价升0.781%，今日最高价为$90.95，而最低价为$87.95，总成交量为46.011万股，总成交金额港币$4.117千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180126132514810_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604204826/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604204826/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2628275533","title":"寶濟藥業(02659)重組烏司他丁(BJ044)IND申請獲受理，開啓重組蛋白藥物新紀元","url":"https://stock-news.laohu8.com/highlight/detail?id=2628275533","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2628275533?lang=zh_tw&edition=fundamental","pubTime":"2026-04-17 15:29","pubTimestamp":1776410984,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，近日，宝济药业宣布，公司自主研发的重组乌司他丁临床试验申请已正式获得国家药品监督管理局受理。数据显示，2023年中国乌司他丁市场规模约为11.6亿元。战略协同：重组技术平台的双轮驱动BJ044的IND受理，与公司另一重点产品重组人糜蛋白酶KJ101的临床进展形成了明确的战略协同。总体而言，BJ044的IND受理不仅是单一产品的进展，更代表了一种具有长期战略价值的技术方向。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429882.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IND","BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":1},{"id":"2627269858","title":"靜脈轉皮下的革命已至，KJ017正式獲批，寶濟藥業（02659）正成為大分子藥物生態的「樞紐核心」","url":"https://stock-news.laohu8.com/highlight/detail?id=2627269858","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627269858?lang=zh_tw&edition=fundamental","pubTime":"2026-04-16 13:36","pubTimestamp":1776317819,"startTime":"0","endTime":"0","summary":"在生物医药“去静脉化”革命浪潮已至的当下，KJ017的正式入场，究竟将如何撬动宝济药业乃至整个皮下给药市场的估值天花板？随着2025年财报中营收数据的首次呈现以及2026年KJ017放量预期的增强，宝济药业有望迎来估值与股价的双重“戴维斯双击”。此次KJ017的获批，将成为宝济药业在港股市场实现价值重构的催化剂，而SJ02与KJ017的协同并进，则为港股生物医药板块树立了一个从技术驱动向场景驱动、从融资驱动向业绩驱动成功转型的可持续增长样本。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1429251.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"静脉转皮下的革命已至，KJ017正式获批，宝济药业（02659）正成为大分子药物生态的“枢纽核心”","news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2627488864","title":"寶濟藥業－Ｂ(02659)出現大手買入6.75萬股，成交價$100.0，涉資675萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2627488864","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2627488864?lang=zh_tw&edition=fundamental","pubTime":"2026-04-13 09:45","pubTimestamp":1776044700,"startTime":"0","endTime":"0","summary":"[大手成交]宝济药业－Ｂ(02659)在上午09:45出现大手买入，成交量为6.75万，成交价为港币$100.0，涉资675万。至目前为止，股价升0.452%，今日最高价为$100.0，而最低价为$98.1，总成交量为18.58万股，总成交金额港币$1.853千万。","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180416150431576_s.png"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604132286/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2604132286/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["02659","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626901462","title":"寶濟藥業－Ｂ(02659)股價上升8.271%，現價港幣$116.5","url":"https://stock-news.laohu8.com/highlight/detail?id=2626901462","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626901462?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 15:25","pubTimestamp":1775719500,"startTime":"0","endTime":"0","summary":"[上升股]宝济药业－Ｂ(02659) 股价在下午03:25比前收市价上升8.271%，现股价为港币$116.5。至目前为止，今日最高价为$116.5，而最低价为$106.8。总成交量为71.784万股，总成交金额为港币$7.97千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180112133337750_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604091965/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAR2604091965/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1139688800","title":"異動解讀 | 核心產品KJ017獲批上市，寶濟藥業-B盤中大漲5.02%","url":"https://stock-news.laohu8.com/highlight/detail?id=1139688800","media":"异动解读","labels":["movement"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1139688800?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 13:58","pubTimestamp":1775714297,"startTime":"0","endTime":"0","summary":"宝济药业-B今日盘中股价大幅拉升，涨幅达到5.02%，引起市场关注。消息面上，公司自主研发的注射用人玻璃酸酶（项目代号KJ017，商品名：葆舒宜®）已获得国家药品监督管理局批准上市，用于辅助皮下输液。该产品作为高度糖基化的重组人玻璃酸酶，能安全、快速地实现大容量皮下给药，解决了静脉通路困难患者的临床难题，其获批标志着公司核心管线取得重要商业化进展。分析指出，KJ017采用基因重组技术，相比传统动物源性产品具有更高的安全性和质量一致性，且在国内市场中进展领先。随着该产品上市，宝济药业有望填补市场空白，并凭借先发优势分享快速增长的国内重组人透明质酸酶市场，这增强了投资者对公司未来盈利能力的信心。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"movement","news_rank":0,"length":0,"strategy_id":0,"source":"ai_movement_cn","symbols":["02659"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2626390318","title":"瞄準生物製藥「卡脖子」難題，寶濟藥業(02659)給出技術驅動高質量發展答案","url":"https://stock-news.laohu8.com/highlight/detail?id=2626390318","media":"智通财经网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2626390318?lang=zh_tw&edition=fundamental","pubTime":"2026-04-09 13:35","pubTimestamp":1775712943,"startTime":"0","endTime":"0","summary":"02 生物制品利好政策纷至沓来，宝济药业致力于填补市场未被满足的需求，解决“卡脖子”风险近年，我国将关键生物制品自主可控视为国家竞争力的一部分，宝济药业主营的生物制药利好政策不断。如此来看，宝济药业KJ107的布局极具战略意义。目前国内市场中，宝济药业的重组人透明质酸酶进展最快，KJ017已获得国家药监局的NDA批准，预计上半年获批上市。KJ103抗GBM病适应症预计2026年上半年启动III期临床。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1426417.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1161","02659"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":6,"pageCount":2,"totalSize":117,"code":"91000000","status":"200"}]}}